Caricamento...
New agents and regimens for diffuse large B cell lymphoma
As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHO...
Salvato in:
| Pubblicato in: | J Hematol Oncol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7734862/ https://ncbi.nlm.nih.gov/pubmed/33317571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01011-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|